MedTrace Logo

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

NCT07354516 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-07-29

No results posted yet for this study

Summary

Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Conditions

  • OAG - Open-Angle Glaucoma
  • OHT - Ocular Hypertension

Interventions

COMBINATION_PRODUCT

QLS-111-FDC

QLS-111-FDC, a PF FDC administered by topical ophthalmic (TO) application for 14 days in the evening (QPM) in both eyes (OU).

DRUG

Latanoprost (0.005%)

PF latanoprost administered by TO application for 14 days QPM OU.

Sponsors & Collaborators

  • Qlaris Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Barbara M Wirostko, MD · Qlaris Bio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-18
Primary Completion
2026-07-22
Completion
2026-07-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07354516 on ClinicalTrials.gov